Study ID	Endpoints
Thacher 2014	Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)a,c
	Source:clinicaltrials.gov/ct2/show/NCT00949832 Primary outcome measure: XR healing of rickets (time frame: 6 months) Secondary outcome measures: alkaline phosphatase (time frame: 6 months), serum calcium (time frame: 6 months), 25‐hydroxy vitamin D (time frame: 6 months), 1,25‐dihydroxy vitamin D (time frame: 2 weeks), calcium absorption (time frame: 1 week) Other outcome measures: — Trial results available in trial register: no
	Endpoints quoted in publication(s)b,c
	Primary outcome measure: combined attainment of a radiographic score of ≤ 1.5 and a serum alkaline phosphatase concentration of ≤ 350 U/L Secondary outcome measure: — Other outcome measures: 25‐hydroxy vitamin D, serum calcium
	Endpoints quoted in abstract of publication(s)b,c
	Primary outcome measures: main outcome measure achievement of a 10‐point radiographic severity score ≤ 1.5 and serum alkaline phosphatase ≤ 350 U/L Secondary outcome measures: — Other outcome measure: 25‐hydroxy vitamin D
Aggarwal 2013	Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)a,c
	Source: CTRI/2010/091/000448 (www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=1634&EncHid=&modid=&compid=%27,%271634det%27) Primary outcome measures: percentage of participants showing complete radiological and biochemical evidence of healing of rickets Secondary outcome measures: — Other outcome measures: — Trial results available in trial register: no
	Endpoints quoted in publication(s)b,c
	Primary outcome measures: improvement in radiological score and biochemical parameters of healing of rickets at 12 weeks Secondary outcome measures: — Other outcome measure: adverse events
	Endpoints quoted in abstract of publication(s)b,c
	Primary outcome measures: — Secondary outcome measures: — Other outcome measures: mean serum 25‐hydroxycholecalciferol D levels, radiological and biochemical evidence of healing rickets, combined endpoint of normal serum alkaline phosphatase and complete radiological healing at 12 weeks
Balasubramanian 2003	Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)a,c
	Source: NT
	Endpoints quoted in publication(s)b,c
	Primary outcome measures: — Secondary outcome measures: — Other outcome measure: healing of rickets
	Endpoints quoted in abstract of publication(s)b,c
	Primary outcome measures: — Secondary outcome measures: — Other outcome measures: healing of rickets, 25 hydroxy vitamin D
Thacher 1999	Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper)a,c
	Source: NT
	Endpoints quoted in publication(s)b,c
	Primary outcome measures: changes in serum calcium and alkaline phosphatase concentrations and radiographic scores Secondary outcome measures: — Other outcome measures: fractures, height, height‐for‐age, weight, serum albumin, serum phosphorus, serum 1,25‐dihydroxy vitamin D concentrations; % of children with the combined outcome of a serum alkaline phosphatase concentration ≤ 350 U/L and radiographic score ≤ 1.5 (indicating nearly complete resolution of the abnormalities) after 24 weeks of treatment)
	Endpoints quoted in abstract of publication(s)b,c
	Primary outcome measures: — Secondary outcome measures: — Other outcome measures: serum calcium concentration, combined endpoint of a serum alkaline phosphatase concentration ≤ 350 U/L and radiographic evidence of nearly complete healing of rickets
—: denotes not reported. aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturer's websites, trial registers). bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents or multiple reports of a primary study). cPrimary and secondary outcomes refer to verbatim specifications in publication/records. Unspecified outcome measures refer to all outcomes not described as primary or secondary outcome measures. EMA: European Medicines Agency; FDA: Food and Drug Administration (US); NT: no trial document available.